First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy

F d'Amore; S Leppa; MC da Silva; T Relander; PD Brown; E Weidmann; GF Lauritzsen; A Pezzutto; A Van Hoof; M van Gelder; JK Doorduijn; KL Wu; JC Kluin-Nelemans; PJ Lugtenburg; M Jankovska; M Merup; UM Fagerli; J Walewski; H Hagberg; JM Mariz; PB Hansen; T Nosslinger; A Janssens; L Brandefors; H Demuynck; MR Schaafsma; I Christiansen; D Salek; S Jyrkkio; V Prochazka; J Zijlstra; L Bohmer; Richard Greil; W Stevens; R Fijnheer; MV Kooy; M Grube; Georg Hopfinger; E Van den Neste; E Jantunen; L Trumper; G Wulf; B Altmann; M Ziepert; M Loeffler; H Toldbod

First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy

F d'Amore, S Leppa, MC da Silva, T Relander, PD Brown, E Weidmann, GF Lauritzsen, A Pezzutto, A Van Hoof, M van Gelder, JK Doorduijn, KL Wu, JC Kluin-Nelemans, PJ Lugtenburg, M Jankovska, M Merup, UM Fagerli, J Walewski, H Hagberg, JM MarizPB Hansen, T Nosslinger, A Janssens, L Brandefors, H Demuynck, MR Schaafsma, I Christiansen, D Salek, S Jyrkkio, V Prochazka, J Zijlstra, L Bohmer, Richard Greil, W Stevens, R Fijnheer, MV Kooy, M Grube, Georg Hopfinger, E Van den Neste, E Jantunen, L Trumper, G Wulf, B Altmann, M Ziepert, M Loeffler, H Toldbod

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Abstract (Journal) › peer-review

Original language	English
Journal	BLOOD
Volume	120
Issue number	21
Publication status	Published - 2012
Event	54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) - Atlanta, GA Duration: 8 Dec 2012 → 11 Dec 2012

Cite this

d'Amore, F., Leppa, S., da Silva, MC., Relander, T., Brown, PD., Weidmann, E., Lauritzsen, GF., Pezzutto, A., Van Hoof, A., van Gelder, M., Doorduijn, JK., Wu, KL., Kluin-Nelemans, JC., Lugtenburg, PJ., Jankovska, M., Merup, M., Fagerli, UM., Walewski, J., Hagberg, H., ... Toldbod, H. (2012). First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy. BLOOD , 120(21).

d'Amore, F ; Leppa, S ; da Silva, MC et al. / First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy. In: BLOOD 2012 ; Vol. 120, No. 21.

@article{0b96114a015a4de2a90eb379e36aae2a,

title = "First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy",

author = "F d'Amore and S Leppa and {da Silva}, MC and T Relander and PD Brown and E Weidmann and GF Lauritzsen and A Pezzutto and {Van Hoof}, A and {van Gelder}, M and JK Doorduijn and KL Wu and JC Kluin-Nelemans and PJ Lugtenburg and M Jankovska and M Merup and UM Fagerli and J Walewski and H Hagberg and JM Mariz and PB Hansen and T Nosslinger and A Janssens and L Brandefors and H Demuynck and MR Schaafsma and I Christiansen and D Salek and S Jyrkkio and V Prochazka and J Zijlstra and L Bohmer and Richard Greil and W Stevens and R Fijnheer and MV Kooy and M Grube and Georg Hopfinger and {Van den Neste}, E and E Jantunen and L Trumper and G Wulf and B Altmann and M Ziepert and M Loeffler and H Toldbod",

year = "2012",

language = "English",

volume = "120",

journal = "BLOOD ",

issn = "0006-4971",

publisher = "American Society of Hematology ",

number = "21",

note = "54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) ; Conference date: 08-12-2012 Through 11-12-2012",

}

d'Amore, F, Leppa, S, da Silva, MC, Relander, T, Brown, PD, Weidmann, E, Lauritzsen, GF, Pezzutto, A, Van Hoof, A, van Gelder, M, Doorduijn, JK, Wu, KL, Kluin-Nelemans, JC, Lugtenburg, PJ, Jankovska, M, Merup, M, Fagerli, UM, Walewski, J, Hagberg, H, Mariz, JM, Hansen, PB, Nosslinger, T, Janssens, A, Brandefors, L, Demuynck, H, Schaafsma, MR, Christiansen, I, Salek, D, Jyrkkio, S, Prochazka, V, Zijlstra, J, Bohmer, L, Greil, R, Stevens, W, Fijnheer, R, Kooy, MV, Grube, M, Hopfinger, G, Van den Neste, E, Jantunen, E, Trumper, L, Wulf, G, Altmann, B, Ziepert, M, Loeffler, M & Toldbod, H 2012, 'First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy', BLOOD , vol. 120, no. 21.

First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy. / d'Amore, F; Leppa, S; da Silva, MC et al.
In: BLOOD , Vol. 120, No. 21, 2012.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy

AU - d'Amore, F

AU - Leppa, S

AU - da Silva, MC

AU - Relander, T

AU - Brown, PD

AU - Weidmann, E

AU - Lauritzsen, GF

AU - Pezzutto, A

AU - Van Hoof, A

AU - van Gelder, M

AU - Doorduijn, JK

AU - Wu, KL

AU - Kluin-Nelemans, JC

AU - Lugtenburg, PJ

AU - Jankovska, M

AU - Merup, M

AU - Fagerli, UM

AU - Walewski, J

AU - Hagberg, H

AU - Mariz, JM

AU - Hansen, PB

AU - Nosslinger, T

AU - Janssens, A

AU - Brandefors, L

AU - Demuynck, H

AU - Schaafsma, MR

AU - Christiansen, I

AU - Salek, D

AU - Jyrkkio, S

AU - Prochazka, V

AU - Zijlstra, J

AU - Bohmer, L

AU - Greil, Richard

AU - Stevens, W

AU - Fijnheer, R

AU - Kooy, MV

AU - Grube, M

AU - Hopfinger, Georg

AU - Van den Neste, E

AU - Jantunen, E

AU - Trumper, L

AU - Wulf, G

AU - Altmann, B

AU - Ziepert, M

AU - Loeffler, M

AU - Toldbod, H

PY - 2012

Y1 - 2012

M3 - Abstract (Journal)

SN - 0006-4971

VL - 120

JO - BLOOD

JF - BLOOD

IS - 21

T2 - 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)

Y2 - 8 December 2012 through 11 December 2012

ER -

d'Amore F, Leppa S, da Silva MC, Relander T, Brown PD, Weidmann E et al. First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy. BLOOD . 2012;120(21).